Improved survival among younger but not among older patients with Multiple Myeloma in the Netherlands, a population-based study since 1989

European Journal of Cancer

Volumn 46, Issue 1, 2010, Pages 160-169

  Schaapveld, Michael ^a,b   Visser, Otto ^a   Siesling, Sabine ^c   Schaar, Cees G ^d   Zweegman, Sonja ^e   Vellenga, Edo ^f  

^a Integraal Kankercentrum Amsterdam   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c Integraal Kankercentrum Noord Nederland   (Netherlands)

^d GELRE HOSPITALS   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Plasma cell myeloma; Survival; Trial participation

Indexed keywords

DEXAMETHASONE; DOXORUBICIN; VINCRISTINE;

ADULT; ADVANCED CANCER; AGE DISTRIBUTION; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NETHERLANDS; POPULATION RESEARCH; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGE FACTORS; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; MALE; MIDDLE AGED; MORTALITY; MULTIPLE MYELOMA; NEOPLASM STAGING; NETHERLANDS; PROGNOSIS; YOUNG ADULT;

EID: 71249109030     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2009.07.006     Document Type: Article

References (26)

1. Association of Comprehensive Cancer Centres [homepage on the Internet]. Utrecht: The Netherlands. http://www.ikcnet.nl/cijfers/index.php?taal=nl&frequentiemaat=1& regio=Landelijk&soort_kanker=50&soort_morfologie=&periode=20 05&inputRegioLandelijk=on&inputRegioMZ=&fInvasief=1&uitk omstmaat=2&periode_input=2005&leeftijdsklassen=1.
2. Alexanian R., Haut A., Khan A.U., et al. Treatment for multiple myeloma: combination chemotherapy with different melphalan dose regimens. JAMA 208 (1969) 1680-1685
3. Samson D., Gaminara E., Newland A., et al. Infusion of vincristine and doxorubicin with oral dexamethasone as first-line therapy for multiple myeloma. Lancet 2 (1989) 882-885
4. Gregory W.M., Richards M.A., and Malpas J.S. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. J Clin Oncol 10 (1992) 334-342
5. Abrahamson G.M., Bird J.M., Newland A.C., et al. A randomized study of VAD therapy with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma. Br J Haematol 94 (1996) 659-664
6. Jagannath S., Barlogie B., Dicke K., et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood 76 (1990) 1860-1866
7. Bladé J., San Miguel J.F., Fontanillas M., et al. Survival of multiple myeloma patients who are potential candidates for early high-dose therapy intensification/ autotransplantation and who were conventionally treated. J Clin Oncol 14 (1996) 2167-2173
8. Tribalto M., Amadori S., Cudillo L., et al. Autologous peripheral blood stem cell transplantation as first line treatment of multiple myeloma: an Italian Multicenter Study. Haematologica 85 (2000) 52-58
9. Hovenga S., de Wolf J.T., Guikema J.E., et al. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: a high incidence of oligoclonal serum Igs post transplantation. Bone Marrow Transplant 25 (2000) 723-728
10. Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 367 (2006) 825-831
11. Facon T., Mary J.Y., Hulin C., et al., Intergroupe Francophone du Myélome. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 370 (2007) 1209-1218
12. San Miguel J.F., Schlag R., Khuageva N.K., et al., VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New Engl J Med 359 (2008) 906-917
13. DurieSalmon SE B.G.M., and Salmon S.E. A clinical staging system for multiple myeloma. Cancer 36 (1975) 842-854
14. Schaar C.G., Kluin-Nelemans H.C., Te Marvelde C., et al., Dutch-Belgian Hemato-Oncology Cooperative Group HOVON. Interferon-alpha as maintenance therapy in patients with multiple myeloma. Ann Oncol 16 (2005) 634-639
15. Segeren C.M., Sonneveld P., van der Holt B., et al., Dutch-Belgian Hemato-Oncology Cooperative Study Group. Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study. Blood 101 (2003) 2144-2151
16. Sonneveld P., van der Holt B., Segeren C.M., et al., Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON). Intermediate-dose melphalan compared with myeloablative treatment in multiple myeloma: long-term follow-up of the Dutch Cooperative Group HOVON 24 trial. Haematologica 92 (2007) 928-935
17. Lokhorst H.M., Schmidt-Wolf I., Sonneveld P., et al., Dutch-Belgian HOVON; German GMMG. Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica 93 (2008) 124-127
18. Lokhorst H., Huijgens P.C., Raymakers R., et al., Myeloomwerkgroep van de Stichting Hemato-Oncologie voor Volwassenen Nederland. Modern treatment methods for multiple myeloma: guidelines from the Dutch Haemato-Oncology Association (HOVON)]. Ned Tijdschr Geneeskd 149 (2005) 808-813
19. Hovenga S., Daenen S.M., de Wolf J.T., et al. Combined thalidomide and cyclophosphamide treatment for refractory or relapsed multiple myeloma patients: a prospective phase II study. Ann Hematol 84 (2005) 311-316
20. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 111 (2008) 2516-2520
21. Brenner H., Gondos A., and Pulte D. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 111 (2008) 2521-2526
22. Kristinsson S.Y., Landgren O., Dickman P.W., Derolf A.R., and Björkholm M. Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. J Clin Oncol 25 (2007) 1993-1999
23. Carli P.M., Coebergh J.W., and Verdecchia A. Variation in survival of adult patients with haematological malignancies in Europe since 1978. Eur J Cancer 34 (1998) 2253-2263
24. Sant M, Allemani C, Santaquilani M, et al., EUROCARE Working Group. EUROCARE-4. Survival of cancer patients diagnosed in 1995-1999. Results and commentary. Eur J Cancer 2009; 45:931-91.
25. Hébert-Croteau N., Brisson J., Lemaire J., and Latreille J. The benefit of participating to clinical research. Breast Cancer Res Treat 91 (2005) 279-281
26. Du Bois A., Rochon J., Lamparter C., Pfisterer J., and AGO Organkommission OVAR PFisterer. Pattern of care and impact of participation in clinical studies on the outcome in ovarian cancer. Int J Gynecol Cancer 15 (2005) 183-191